Aquestive Therapeutics
AQST
65 hedge funds and large institutions have $102M invested in Aquestive Therapeutics in 2020 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 21 reducing their positions, and 10 closing their positions.
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
8% more funds holding
Funds holding: 60 → 65 (+5)
6% more capital invested
Capital invested by funds: $96.5M → $102M (+$5.87M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.21% less ownership
Funds ownership: 59.15% → 56.93% (-2.2%)
19% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 21
67% less call options, than puts
Call options by funds: $295K | Put options by funds: $898K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
+$2.44M |
| 2 |
Renaissance Technologies
New York
|
+$1.63M |
| 3 |
Nisa Investment Advisors
St. Louis,
Missouri
|
+$390K |
| 4 |
Squarepoint
New York
|
+$256K |
| 5 |
Bank of New York Mellon
New York
|
+$234K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$3.64M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$2.42M |
| 3 |
PA
Perceptive Advisors
New York
|
-$2.18M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$548K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$501K |
AQST Hedge Fund Activity: Q4 2020 in Review
65 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q4 2020, worth a combined $102M — up 6.1% from $96.5M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new AQST positions and 10 closed out — a net gain of 5 holders — while 17 added to existing stakes and 21 trimmed.
The largest buyer was Nuveen, adding an estimated $2.44M. The largest seller was Morgan Stanley, cutting an estimated $3.64M.
- 65 institutional investors held Aquestive Therapeutics (AQST) as of Q4 2020, up from 60 in Q3 2020.
- Funds reported $102M of Aquestive Therapeutics stock for Q4 2020, up 6.1% quarter-over-quarter.
- 15 funds opened new Aquestive Therapeutics positions in Q4 2020 and 10 closed out, a net change of +5 holders.
- The largest Aquestive Therapeutics buyer in Q4 2020 was Nuveen, an estimated $2.44M added.
- The largest Aquestive Therapeutics seller in Q4 2020 was Morgan Stanley, an estimated $3.64M sold.
Based on aggregated 13F filings for Q4 2020.